These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 9460772)

  • 21. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
    Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
    Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B: time for a new "gold standard".
    Ostrosky-Zeichner L; Marr KA; Rex JH; Cohen SH
    Clin Infect Dis; 2003 Aug; 37(3):415-25. PubMed ID: 12884167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of the lipid formulations of amphotericin B.
    Dupont B
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
    González GM; Tijerina R; Najvar LK; Bocanegra R; Rinaldi MG; Graybill JR
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2140-3. PubMed ID: 15155212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C; Castagnola E
    Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
    Loo AS; Muhsin SA; Walsh TJ
    Expert Opin Drug Saf; 2013 Nov; 12(6):881-95. PubMed ID: 23931455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of lipid formulations of amphotericin B for systemic fungal infections.
    Leenders AC; de Marie S
    Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomal amphotericin B in neonates with invasive candidiasis.
    Al Arishi H; Frayha HH; Kalloghlian A; Al Alaiyan S
    Am J Perinatol; 1998; 15(11):643-8. PubMed ID: 10064206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells.
    Reyes E; Cardona J; Prieto A; Bernstein ED; Rodríguez-Zapata M; Pontes MJ; Alvarez-Mon M
    J Infect Dis; 2000 Jun; 181(6):2003-10. PubMed ID: 10837182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B colloidal dispersion.
    Patel R
    Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
    Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
    Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current role of amphotericin B lipid complex in managing systemic fungal infections.
    Chu P; Sadullah S
    Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs.
    Krawiec DR; McKiernan BC; Twardock AR; Swenson CE; Itkin RJ; Johnson LR; Kurowsky LK; Marks CA
    J Am Vet Med Assoc; 1996 Dec; 209(12):2073-5. PubMed ID: 8960189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.